The Norwood Scale: Seven Stages, Plus Everything It Gets Wrong matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
A friend of mine, a 28-year-old software developer in Austin named Raj, texted me a photo of his hairline last November with the message: “Is this a 2 or a 3?” He’d been staring at Norwood scale charts on Reddit for weeks, zooming into his temples in bathroom mirrors, comparing himself to grainy reference images. The problem wasn’t that the scale was unhelpful. The problem was that he fell squarely between stages, his thinning was partly diffuse, and the chart gave him no vocabulary for that. His experience is incredibly common, and it’s the reason this article exists.
The Norwood scale is the standard classification system for male pattern hair loss. It works reasonably well as a communication tool between clinicians, and it’s useful for orienting patients to the general trajectory of androgenetic alopecia. But it also has real gaps: ambiguous mid-stages, a poor fit for diffuse thinners, and variant patterns that confuse people trying to self-assess. Here’s how the system actually works, where the biology fits in, what treatments the evidence supports, and when you should stop Googling and see a dermatologist.
A Classification System Built in Two Halves
The scale’s origin story matters because it explains the system’s limitations. James Hamilton published the foundational work in 1951 in the Annals of the New York Academy of Sciences, documenting how men castrated before puberty never developed typical recession or crown thinning. That paper established the androgen connection. Hamilton proposed a simple three-stage classification.
In 1975, O’Tar Norwood expanded the framework to seven stages with several variant subtypes in the Southern Medical Journal. The big addition was the Type A variant, where loss moves front-to-back in a band rather than through the classic bitemporal-plus-vertex pattern. This distinction matters clinically because Type A progression looks quite different from what most people picture when they think of “going bald,” and it’s frequently missed in self-assessment.
The combined Hamilton-Norwood scale has survived for over 70 years largely because it’s simple enough for consistent use across observers while capturing enough variation to be clinically meaningful. Alternatives exist (the BASP classification proposed in 2007 is the most notable), but none have displaced the Norwood in routine practice. It’s like the BMI of hair loss: imperfect, sometimes misleading, but entrenched because nothing better has gained traction.
The Biology Underneath the Stages
Each Norwood stage describes a visible pattern, but the engine driving that pattern is follicular miniaturization, and understanding it changes how you think about treatment timing.
Dihydrotestosterone (DHT), produced from testosterone by the enzyme 5-alpha reductase, binds to androgen receptors in genetically susceptible follicles. Over successive growth cycles, the anagen (growth) phase shortens, the telogen (resting) phase lengthens, and the dermal papilla physically shrinks. Thick terminal hairs become thinner, shorter, and eventually wispy vellus hairs that contribute almost nothing to visible coverage. This process is gradual, which is why people argue over whether they’re a Norwood 2 or a Norwood 3 for years.
The genetics are polygenic. Yes, the androgen receptor gene on the X chromosome (inherited from the maternal side) is involved, which is why people look at their mother’s father. But paternal genetics and other autosomal loci contribute meaningfully. Your grandfather’s scalp is a rough signal, not a forecast.
Two drugs target this pathway directly. Finasteride blocks the type II isoform of 5-alpha reductase. Dutasteride blocks both type I and type II, lowering scalp DHT more aggressively. Both have documented effects on hair density in randomized trials, with dutasteride showing larger improvements in head-to-head comparisons (Olsen et al., JAAD, 2006).
How Dermatologists Actually Evaluate Hair Loss
Here’s where the Norwood scale fits into clinical practice, and also where self-assessment usually breaks down.
A proper dermatology workup includes patient history, family history, scalp examination, trichoscopy (dermoscopy of the scalp), and selective lab work. The American Academy of Dermatology’s clinical guidelines are clear that visual pattern recognition alone isn’t sufficient.
Trichoscopy reveals things the naked eye cannot: hair shaft diameter variability (caliber variability of 20% or more is a key finding), yellow dots representing empty follicular ostia, and decreased follicular unit density in affected areas with preservation of the occipital donor zone. This is what separates a clinical Norwood staging from squinting at your hairline in a phone camera.
Lab testing is selective. Ferritin, TSH, vitamin D, and CBC are reasonable when telogen effluvium is suspected or in patients with diffuse thinning. The AAD does not recommend routine androgen panels in men with classic pattern loss because the diagnosis is clinical.
Here’s my genuinely held opinion: most men spend too long self-staging and too little time getting a single trichoscopy appointment. A 20-minute visit with a dermatoscope provides more useful information than six months of Reddit comparisons. The cost is usually $150 to $250 out of pocket, or covered if you have dermatology benefits.
Patients interested in understanding where they fall on the staging system can review a complete norwood scale walkthrough, which provides photographic staging examples and additional clinical context. But photos are orientation, not diagnosis.
What Treatments the Evidence Actually Supports (and What They Cost)
Treatment works best when started early, before substantial follicular dropout. That’s the boring truth everyone hates hearing. Once follicles are gone, medical therapy can’t regenerate them.
Finasteride 1 mg daily has the largest evidence base. The original five-year randomized trial (JAAD, 2002) showed sustained improvements in hair count versus placebo. Generic finasteride costs $10 to $25/month at US pharmacies with discount cards, and as little as $5 to $15 through direct-to-consumer telehealth. Branded Propecia runs $70 to $90/month with no documented clinical advantage. Reported sexual side effects affect a small percentage of users in randomized trials and are generally reversible on discontinuation.
Topical minoxidil 5% (twice daily) is FDA-approved over the counter. The mechanism isn’t fully understood but involves potassium channel opening and direct follicular effects that prolong anagen. Results typically appear at three to six months. Cost: $10 to $30/month generic.
Low-dose oral minoxidil (0.25 to 5 mg daily) is increasingly prescribed off-label following Vañó-Galván et al.’s 2021 multicenter safety study of 1,404 patients in JAAD, which documented manageable side-effect profiles at low doses. Periorbital edema and hypertrichosis are the main concerns. Under $15/month in generic form; the cost driver is the prescribing visit.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published smaller randomized trials with positive but variable results (Gentile & Garcovich, 2020). They’re reasonable additions to medical therapy, not substitutes. PRP runs $500 to $1,500 per session, with most protocols calling for three to four sessions the first year. That first-year cost can match or exceed a full year of combination medical therapy.
Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles. In the US, FUE costs $4 to $10 per graft; a typical 2,500-to-3,500 graft case runs $10,000 to $35,000. Turkish clinics offer $2,000 to $5,000 for similar graft counts, reflecting labor cost differences, not necessarily quality differences. Most experienced surgeons are cautious about operating on patients in their 20s because the long-term progression pattern isn’t established yet.
Insurance generally classifies all of this as cosmetic. HSAs and FSAs may cover prescribed medications and physician visits but typically not surgical procedures.
Lifestyle Factors: What’s Real and What’s Noise
Pattern hair loss is genetically determined. Full stop. But several lifestyle factors influence the rate of shedding.
Smoking accelerates loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium. Iron repletion in deficient patients helps. Iron supplementation in iron-replete patients does nothing.
Severe acute stress triggers telogen effluvium starting two to three months after the event, typically resolving within six to nine months. (It may also unmask underlying pattern loss that was previously subclinical.)
Anabolic steroid use accelerates pattern loss in susceptible men through supraphysiologic androgen exposure, with effects that may not fully reverse after stopping.
Severe caloric restriction and rapid weight loss reliably produce telogen effluvium. Modest dietary improvements beyond correcting specific deficiencies don’t produce visible hair benefits. That supplement stack someone’s selling you is almost certainly a waste of money.
When to Stop Self-Assessing and See Someone
Self-management is reasonable in many cases, particularly for early-stage pattern loss in men who want to start finasteride and minoxidil. But several scenarios require in-person evaluation:
Sudden diffuse shedding in the last six months (likely telogen effluvium, which needs workup, not pattern-loss meds). Patchy loss with smooth bald spots (possible alopecia areata, an autoimmune condition). Scalp pain, burning, redness, scaling, or scarring (possible scarring alopecia like lichen planopilaris or frontal fibrosing alopecia, which require prompt diagnosis to prevent permanent follicular destruction, per Kassira et al., JAAD, 2017). Hair loss in women with menstrual irregularities, acne, or excess body hair (warrants endocrine evaluation). Rapid progression of more than one Norwood stage per year in a young patient. And loss that hasn’t responded to documented standard medical therapy over 12 months.
The AAD’s position is straightforward: any progressive hair loss that concerns the patient is a legitimate reason for a dermatology consultation.
FAQs
How accurate are AI hair-loss assessment tools? They provide reasonable orientation for self-screening but do not replace dermatologic evaluation. Best used as a starting point for understanding likely stage and treatment options, not as diagnosis.
Should I get a hair transplant if I am in my 20s? Experienced surgeons approach this cautiously because the long-term progression pattern isn’t yet established. Medical therapy to stabilize native hair is usually prioritized first.
Are hair transplants permanent? Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. Surrounding native hair may continue thinning, which is why most patients continue medical therapy after transplantation.
Can pattern hair loss be reversed? Partially, in some patients, with early treatment. Combination finasteride and minoxidil started before substantial follicular dropout produces the best results. Late-stage loss with extensive miniaturization is generally not reversible with medical therapy alone.
Is finasteride safe? Finasteride is FDA-approved at 1 mg daily for pattern hair loss with a well-characterized safety profile across more than two decades. Sexual dysfunction is reported in a small percentage of users in randomized trials and is generally reversible on discontinuation. Discuss risks and benefits with a prescribing clinician.
Is the Norwood scale used for women? No. Female pattern hair loss is classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
What Norwood stage is “too late” for treatment? There’s no absolute cutoff, but patients at Norwood 6 or 7 with widespread follicular dropout are unlikely to see meaningful regrowth from medical therapy alone. Hair transplantation becomes the primary option, and donor capacity may limit what’s achievable.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
